Get regular updates to your inbox.
Medications that block the activity of the pro-inflammatory molecule interleukin-17A (IL-17A) can ease symptoms of ankylosing spondylitis (AS), but further research is needed to evaluate their safety, according to an analysis. These findings were in the study “Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing…
Read more
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare disease patients overall give their healthcare experience a medium-low rating, of 2.5 on a scale of 1 to 5,…
The U.S. Food and Drug Administration (FDA) has cleared the start of a Phase 2 trial of izokibep in people with ankylosing spondylitis (AS), according to the therapy’s developers Affibody AB and Inmagene Biopharmaceuticals. “Obtaining FDA IND [investigational new drug] clearance is an important milestone for the izokibep…
Having supportive loved ones and doctors who validate your pain is essential with an invisible illness, writes columnist Janneke Phung.
Want to stay up to date on all the latest on ankylosing spondylitis? Click the link below to find more news and information.
Ankylosing spondylitis (AS) is a type of arthritis that mainly affects the joints of the spine. Inflammation of the spaces between the vertebrae causes back pain and stiffness.
There is no single specific test to diagnose AS, and many of the symptoms (such as back pain) also can be caused by other conditions. A diagnosis often involves checking for common hallmarks of AS.
Patients’ symptoms usually progress gradually over time. They may be erratic because the type and severity of the symptoms can improve, worsen, or completely stop for periods of time.
Get regular updates to your inbox.
